Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$5.25 USD
+0.70 (15.38%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $5.35 +0.10 (1.90%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Kyverna Therapeutics, Inc. (KYTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$31.33 | $48.00 | $7.00 | 588.57% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Kyverna Therapeutics, Inc. comes to $31.33. The forecasts range from a low of $7.00 to a high of $48.00. The average price target represents an increase of 588.57% from the last closing price of $4.55.
Analyst Price Targets (6 )
Broker Rating
Kyverna Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on five recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.40 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/10/2024 | UBS | Trung Huynh | Not Available | Strong Buy |
10/9/2024 | Rodman & RenshawCo. | Tony Butler | Not Available | Strong Buy |
7/3/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Not Available | Hold |
6/17/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
3/4/2024 | Wells Fargo Securities | Derek C Archila | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 7 |
Average Target Price | $28.71 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.77 |
KYTX FAQs
Kyverna Therapeutics, Inc. (KYTX) currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Kyverna Therapeutics, Inc. (KYTX) is $28.71. The current on short-term price targets is based on 4 reports.
The forecasts for Kyverna Therapeutics, Inc. (KYTX) range from a low of $7 to a high of $48. The average price target represents a increase of $446.86 from the last closing price of $5.25.
The current UPSIDE for Kyverna Therapeutics, Inc. (KYTX) is 446.86%
Based on short-term price targets offered by six analysts, the average price target for Kyverna Therapeutics, Inc. comes to $31.33. The forecasts range from a low of $7.00 to a high of $48.00. The average price target represents an increase of 588.57% from the last closing price of $4.55.